Latest & greatest articles for Topical Corticosteroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Topical Corticosteroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Topical Corticosteroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Topical Corticosteroid

1. Topical medium potency corticosteroids compared to PUVA (psoralen plus ultraviolet A radiation) for the treatment of pompholyx in adult patients

Topical medium potency corticosteroids compared to PUVA (psoralen plus ultraviolet A radiation) for the treatment of pompholyx in adult patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

2. Different strategies for using topical corticosteroids in people with eczema [Cochrane protocol]

Different strategies for using topical corticosteroids in people with eczema [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

3. Emollients and topical corticosteroids for treatment of atopic dermatitis: a systematic review of guidelines

Emollients and topical corticosteroids for treatment of atopic dermatitis: a systematic review of guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

4. Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers

Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers UTCAT3273, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Topical Corticosteroids Improve Healing Time in Patients with Aphthous Ulcers Clinical Question In patients with aphthous ulcers, does treatment with topical corticosteroids, as compared to a placebo, improve healing time of the ulcers? Clinical Bottom Line Patients treated (...) with topical corticosteroids show an improved ulcer healing time. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Staines/2015 8 studies/583 patients Systematic review of randomized trials Key results 5 of the 8 studies in which ulcer duration was evaluated found that application of topical corticosteroids decreased the time required for the ulcer to heal (P Evidence Search “recurrent” AND “aphthous

2017 UTHSCSA Dental School CAT Library

5. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. (PubMed)

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab (...) substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic dermatitis.In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS

2017 Lancet

7. Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids

Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids Chronic, recurring, inflammatory disorder of the skin. Often referred to as eczema, but they are not interchangeable terms: Eczema is a group of skin conditions, which (...) appropriate. Symptoms are interfering with quality of life and sleep Nummular discoid eczema - small round plaques of small papules and blisters, usually on trunk or extremities - recommended treatment is potent topical corticosteroids. Large areas of skin are involved (> 30 % of body surface area) - risk of systemic absorption of corticosteroid if large areas of skin are being treated. Pediatric patients may be at higher risk of topical corticosteroid-induced HPA axis suppression and Cushing's syndrome

Full Text available with Trip Pro

2017 medSask

8. Long-term topical corticosteroid use and risk of skin cancer: a systematic review protocol. (PubMed)

Long-term topical corticosteroid use and risk of skin cancer: a systematic review protocol. The objective of this systematic review is to synthesize the best available research evidence to determine the risk of skin cancer in patients on long-term use of topical corticosteroids. Specifically the review question is: In people using long-term (regular use over one month) topical corticosteroids, what is the risk of developing skin cancer (clinically or histologically confirmed basal cell

Full Text available with Trip Pro

2016 JBI database of systematic reviews and implementation reports

9. Psoriasis patients’ experiences concerning medical adherence to treatment with topical corticosteroids (PubMed)

Psoriasis patients’ experiences concerning medical adherence to treatment with topical corticosteroids Nonadherence to topical treatment of psoriasis is a common cause of treatment failure. This focus group study was conducted to obtain the patients' own experiences and explanations regarding medical adherence. The participants consisted of eight primary adherent patients with moderate psoriasis treated with corticosteroid or corticosteroid-calcipotriol combinations, purposefully sampled (...) in the prescriber, diverging information from health care personnel, experiencing side effects, having fear of side effects, impractical formulations of topical products, and impatience regarding time before an effect of the treatment was observed. From this study, the recommendations for the prescribing doctor to improve medical adherence are, the doctor needs to take time to listen to the patient, prescribe a topical product that is easy to apply and less greasy, inform the patients about benefits from

Full Text available with Trip Pro

2016 Psoriasis (Auckland, N.Z.)

10. Systematic review: Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic rhinosinusitis

Systematic review: Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic rhinosinusitis Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic rhinosinusitis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Best evidence supports topical corticosteroids and routine saline irrigations for medical treatment of chronic

2016 Evidence-Based Medicine (Requires free registration)

11. Association of Topical Corticosteroid Use and Bone Mineral Density in Patients with Atopic Dermatitis

Association of Topical Corticosteroid Use and Bone Mineral Density in Patients with Atopic Dermatitis "Association of Topical Corticosteroid Use and Bone Mineral Density in " by Carsten Paulson < > > > > > Title Author Date of Graduation Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background Atopic dermatitis (AD) is a common pruritic inflammatory skin disease. First-line (...) therapy for AD involves the use of topical corticosteroids. With long-term use, these agents exert systemic effects and have been associated with adverse effects on bone health. This review assesses the current evidence for an association between topical corticosteroid use and bone mineral density in patients with atopic dermatitis. Methods An exhaustive search of available literature was conducted in using the MEDLINE-Ovid, Web of Science, CINAHL, and Evidence-Based Medicine Reviews Multifile

2015 Pacific University EBM Capstone Project

12. Corticosteroids - topical (skin), nose, and eyes

Corticosteroids - topical (skin), nose, and eyes Corticosteroids - topical (skin), nose, and eyes - NICE CKS Clinical Knowledge Summaries Share Corticosteroids - topical (skin), nose, and eyes: Summary Corticosteroids are synthetic analogues of the natural hormones that are produced by the adrenal cortex. Local corticosteroids are predominantly glucocorticoids. They have 4 main effects: Anti-inflammatory. Immunosuppressive. Anti-proliferative (anti-mitotic). Vasoconstrictive. Topical (...) , or infection. The length of treatment with topical corticosteroids depends on the diagnosis. Generally, very potent corticosteroids should not be used for more than 3 weeks continuously. If treatment is indicated for longer, intermittent dosing and gradual tapering of the dose should be considered, and more frequent monitoring for adverse effects should be arranged. Less potent topical corticosteroids can be used for up to 3 months, except in intertriginous areas, on the face and neck, or under occlusion

2015 NICE Clinical Knowledge Summaries

13. Topical corticosteroids as adjunctive therapy for bacterial keratitis. (PubMed)

Topical corticosteroids as adjunctive therapy for bacterial keratitis. Bacterial keratitis is a serious ocular infectious disease that can lead to severe visual disability. Risk factors for bacterial corneal infection include contact lens wear, ocular surface disease, corneal trauma, and previous ocular or eyelid surgery. Topical antibiotics constitute the mainstay of treatment in cases of bacterial keratitis, whereas the use of topical corticosteroids as an adjunctive therapy to antibiotics (...) remains controversial. Topical corticosteroids are usually used to control inflammation using the smallest amount of the drug. Their use requires optimal timing, concomitant antibiotics, and careful follow-up.The objective of the review was to assess the effectiveness and safety of corticosteroids as adjunctive therapy for bacterial keratitis. Secondary objectives included evaluation of health economic outcomes and quality of life outcomes.We searched CENTRAL (which contains the Cochrane Eyes

Full Text available with Trip Pro

2014 Cochrane

14. Topical corticosteroids for treating phimosis in boys. (PubMed)

Topical corticosteroids for treating phimosis in boys. Until recently, phimosis has been treated surgically by circumcision or prepuceplasty; however, recent reports of non-invasive treatment using topical corticosteroids applied for four to eight weeks have been favourable. The efficacy and safety of topical corticosteroids for treating phimosis in boys has not been previously systematically reviewed.We aimed to 1) compare the effectiveness of the use of topical corticosteroid ointment applied (...) to the distal stenotic portion of the prepuce in the resolution of phimosis in boys compared with the use of placebo or no treatment, and 2) determine the rate of partial resolution (improvement) of phimosis, rate of re-stenosis after initial resolution or improvement of phimosis, and the rate of adverse events of topical corticosteroid treatment in boys with phimosis.We searched the Cochrane Renal Group's Specialised Register through contact with the Trials' Search Co-ordinator using search terms relevant

2014 Cochrane

15. Topical corticosteroids effective for nasal polyps

Topical corticosteroids effective for nasal polyps Topical corticosteroids effective for nasal polyps | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Topical corticosteroids effective for nasal polyps Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2013 Cochrane PEARLS

16. A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care

A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please (...) try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Study found that the use of topical intranasal corticosteroids is very unlikely to be a clinically effective treatment for otitis media with effusion in children in the primary care

2009 NIHR HTA programme

17. Safety of topical corticosteroids in pregnancy. (PubMed)

Safety of topical corticosteroids in pregnancy. Topical corticosteroids are the most frequently prescribed dermatological treatment and are frequently used by pregnant women with skin conditions. However, little is known about their safety in pregnancy.To assess the effects of topical corticosteroids on pregnancy outcomes.On 5th May 2009 we searched the Cochrane Skin Group Specialised Register, the Cochrane Pregnancy and Childbirth Group Specialised Register, CENTRAL (The Cochrane Library 2009 (...) , Issue 2), MEDLINE (from 2003), and EMBASE (from 2005). We searched LILACS, CINAHL, British Nursing Index, SCI-EXPANDED, BIOSIS Previews, Conference Papers Index, and Conference Proceedings Citation Index-Science from inception to May 2009. We scanned the bibliographies of the included studies, published reviews, and articles that had cited the included studies. Pharmaceutical companies that have introduced an original topical corticosteroid product were contacted.Randomised controlled trials

2009 Cochrane

18. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. (PubMed)

Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. To determine the clinical effectiveness of topical intranasal corticosteroids in children with bilateral otitis media with effusion.Double blind randomised placebo controlled trial.76 Medical Research Council General Practice Research Framework practices throughout the United Kingdom, between 2004 and 2007.217 (...) ) at one month (primary end point), three months, and nine months; adverse events; three month diary symptoms. Results 41% (39/96) of the topical steroid group and 45% (44/98) of the placebo group were cured in one or both ears at one month (difference favouring placebo 4.3% (95% confidence interval -9.3% to 18.1%). Poisson regression was done with adjustment for four pre-specified covariates (clinical severity, P=0.003; atopy, P=0.67; age, P=0.92; season, P=0.71). The adjusted relative risk at one

Full Text available with Trip Pro

2009 BMJ

19. A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care

A double-blind randomised placebo controlled trial of topical intranasal corticosteroids in 4- to11-year-old children with persistent bilateral otitis media with effusion in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 Health Technology Assessment (HTA) Database.

20. Topical corticosteroids as adjunctive therapy for bacterial keratitis. (PubMed)

Topical corticosteroids as adjunctive therapy for bacterial keratitis. Bacterial keratitis is a serious ocular infectious disease that can lead to severe visual disability. Risk factors for bacterial corneal infection include contact lens wear, ocular surface disease, corneal trauma and previous ocular or eyelid surgery. Topical antibiotics constitute the mainstay of treatment in cases of bacterial keratitis where as the use of topical corticosteroids remains controversial. Topical (...) , an online database of ongoing trials (www.clinicaltrials.gov), reference lists of included trials, earlier reviews and the American Academy of Ophthalmology guidelines. We also contacted experts to identify any unpublished and ongoing randomized trials.We included randomized controlled trials evaluating adjunctive therapy with topical corticosteroids in people with bacterial keratitis.Two review authors independently screened all the retrieved articles. Methodological quality of the one included trial

Full Text available with Trip Pro

2007 Cochrane